With biosimilars of Eylea (aflibercept) expected to reach the Japanese market in November, all eyes are on whether the originator’s…
BUSINESS
Hutchmed’s Colorectal Cancer Med Accepted for European Review: Takeda
Takeda Pharmaceutical said on June 15 that the European Medicines Agency (EMA) has accepted for review a regulatory application for fruquintinib, licensed from China ally Hutchmed, for the treatment of adult patients with previously treated metastatic colorectal cancer (CRC). The…
To read the full story
Related Article
- Takeda Scores EU Approval for Colorectal Cancer Med Fruzaqla
June 25, 2024
- Takeda Gets US Clearance for Hutchmed’s Colorectal Cancer Drug
November 10, 2023
- Takeda Seeks Japan Nod for Hutchmed’s Colorectal Cancer Drug
October 2, 2023
- Hutchmed’s Colorectal Cancer Med Gets FDA’s Priority Review: Takeda
May 29, 2023
- Hutchmed’s Colorectal Cancer Med Logs Positive Data in Japanese Cohort: Takeda
March 24, 2023
- Takeda Gets Rights to Hutchmed’s Colorectal Cancer Med Outside China
January 25, 2023
BUSINESS
- Nichi-Iko to Offload AGs of Allegra and Plavix to Meiji Group
October 8, 2025
- NHI-Market Price Gap Likely to Narrow Further in 2025; Will It Drop into 4% Zone?
October 8, 2025
- Kissei Grants Linzagolix Rights to Searchlight in Canada
October 8, 2025
- Enhertu Combo Filed for First-Line HER2 Breast Cancer in Japan
October 8, 2025
- Leqembi Iqlik Autoinjector Now Available in US: Eisai/Biogen
October 8, 2025
In the dynamic pharmaceutical landscape, especially within the nuanced Japanese market, leadership hinges on acute awareness. This transcends surface-level observations, demanding a deep understanding of regulatory shifts, cultural sensitivities, and evolving patient needs. For leaders in this sector, particularly those…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…